PARSIPPANY, N.J., Jan. 28, 2016 /PRNewswire/ -- Interpace Diagnostics (NASDAQ: IDXG) announced today new analyses of data from a multicenter study of 492 patients have been published online in the journal Diagnostic Pathology.  A link to the study, titled, "Influence of Integrated Molecular Pathology Test Results on Real-World Management Decisions for Patients with Pancreatic Cysts: Analysis of Data from a National Registry Cohort," can be found here: http://www.diagnosticpathology.org/content/11/1/5

The purpose of the analyses was to determine if adjunctive use of PancraGen® testing in standard clinical practice influenced management decisions for intervention or surveillance of patients with pancreatic cystic lesions.  PancraGen® is the Company's proprietary pancreatic molecular diagnostic test.  "The high mortality of pancreatic cancer must be carefully balanced with risks associated with pancreatic surgery, including lifelong morbidities and death. In the study, PancraGen results clearly influenced management decisions for cystic disease in such a way that was beneficial to patient outcomes," said Sydney Finkelstein, M.D., Chief Scientific Officer and Medical Director of Interpace Diagnostics.

The analyses show that when PancraGen results indicated low risk of cancer, 55% of patients underwent surveillance instead of guideline-recommended surgery, with benign disease present in 99% at approximately 3 years follow-up. Furthermore, when PancraGen results indicated high risk, 88% of patients underwent surgery instead of guideline-recommended surveillance and malignancy was present in 57%.

The investigation was led by Drs. David Loren, Thomas Kowalski and Ali Siddiqui, Department of Medicine, Jefferson Digestive Disease Institute, Thomas Jefferson University, Philadelphia, PA; Drs. Nidhi Malhotra and Nadim Haddad, Division of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC.

About Interpace Diagnostics Group, Inc. 
Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.  These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, the market's acceptance of our molecular diagnostic tests; our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the company's periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 5, 2015 and in the company's Form 10-Q filed with the SEC on November 12, 2015. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pancragen-clinical-utility-study-published-in-diagnostic-pathology-300211170.html

SOURCE Interpace Diagnostics Group, Inc.